Lilly's Jaypirca Gains Traction in EU for Chronic Lymphocytic Leukemia Treatment Eli Lilly's Jaypirca (pirtobrutinib) has received a favorable opinion from the EU's CHMP for chronic lymphocytic leukemia in previously treated patients, marking a potential breakthrough in therapy options.

Lilly's Jaypirca Gains Traction in EU for Chronic Lymphocytic Leukemia Treatment #United_States #Indianapolis #BTK_Inhibitor #Pirtobrutinib #CLL_Treatment

Potential of Ascentage Pharma's Lisaftoclax in Treating CLL/SLL Showcased at ASH 2024 At ASH 2024, Ascentage Pharma unveiled promising clinical data for Lisaftoclax, a Bcl-2 inhibitor, showing effectiveness in CLL patients previously treated with Venetoclax.

Potential of Ascentage Pharma's Lisaftoclax in Treating CLL/SLL Showcased at ASH 2024 #USA #San_Diego #Ascentage_Pharma #Lisaftoclax #CLL_Treatment